Study Finds Tarceva Benefits Older Lung Cancer Patients
Mon, 19 Sep 2005 02:00 AM EST
... The tyrosine kinase inhibitor erlotinib (Tarceva®) showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer (NSCLC), reports a team led by investigators from Dana-Farber Cancer Institute in Boston. ...
Related Topics
- Tarceva
- Lung Cancer
- Older Adults
- Small Cell Lung Cancer
- Lung Diseases & Disorders
- Cancers
- Black Lung
- Gefitinib
- Metastatic Cancer
- Non-Small Cell Lung Cancer
- Brain Cancer
- Smoking Cessation and Continued Risk in Cancer Patients
- Liver Cancer
- Thyroid Cancer
- Respiratory Diseases
- Cancer
- Pemetrexed for Injection
- Bevacizumab Injection
- Cancer--Living with Cancer
- Cancer Alternative Therapy

Not Signed In -


